The transcription factors p53 and E2F-1 play important roles in the control of cell cycle progression. In transient transfection experiments, expression of E2F-1, other E2F family members, or p53 squelched transcription from cotransfected plasmids in a dose-dependent manner. Although the proteasome inhibitors MG-132 and lactacystin markedly increased the level of expression of E2F-1 and p53, these inhibitors completely alleviated squelching by both proteins. Several observations indicate MG-132 alleviates squelching by in¯uencing the conformation of newly synthesized p53 and E2F-1: MG-132 increased the fraction of wild type p53 bound by a monoclonal antibody which preferentially recognizes mutant conformers of p53, increased binding of hsp70 to p53 and inhibited nuclear accumulation of both p53 and E2F-1, but not the pocket protein p107. The protease inhibitors ALLN and ALLM did not in¯uence expression of E2F-1 or p53, nor did they alleviate squelching by either transcription factor. Because MG-132 and lactacycstin are highly speci®c inhibitors of the proteasome protease, our results suggest that the proteasome in¯uences post-translational processes involved in proper folding and cytoplasmic clearing of E2F-1 and p53.
Introduction
E2F is a family of heterodimeric transcription factors that regulate expression of genes involved in cell cycle progression and DNA replication. The transcriptionally active forms of E2F appear to be heterodimers, with one subunit encoded by the E2F-like gene family and one subunit encoded by the DP-like gene family (reviewed by Slansky and Farnham, 1996) . To date, seven molecules which contribute to E2F activity have been isolated from mammalian cells. E2F-1 was isolated by virtue of its speci®c intereaction with the retinoblastoma tumor suppressor gene product, pRb (Helin et al., 1992; Kaelin et al., 1992; Shan et al., 1992) . Three similar factors, E2F-2, E2F-3 and E2F-4, were isolated by homology to E2F-1 (Ivey-Hole et al., 1993; Lees et al., 1993; Ginsberg et al., 1994) . Recently, E2F-4 and E2F-5 were also isolated as protein factors that bind the pRb-related proteins p107 and p130 (Beijersbergen et al., 1994; Hijmans et al., 1995; Sardet et al., 1995) . In other studies, DP-1 was isolated as a factor with E2F-like activity from mouse embryonic carcinoma F9 cells (Girling et al., 1993) , and DP-2 was found by homology to DP-1 (Wu et al., 1995) .
Several lines of evidence indicate that the interaction of E2F with the retinoblastoma family of pocket proteins plays a central role in the regulation of genes involved in the G1 to S phase transition and DNA replication (reviewed by Farnham et al., 1993; Lam and LaThangue, 1994; Adams and Kaelin, 1995) . Viral oncoproteins such as E1A and E7 inhibit the association of E2F with pRb family members, and thereby mimic the normal cell cycle events that lead to E2F activation (Whyte et al., 1988; Bagchi et al., 1990 Bagchi et al., , 1991 Dyson et al., 1989; Chellapan et al., 1991; Weintraub et al., 1992) . Recent work suggests association with retinoblastoma family members or adenovirus transforming proteins protects E2F subunits from degradation by the ubiquitin-proteasome pathway (Hofmann et al., 1996; Hateboer et al., 1996) .
Overexpression of E2F induces cells into S-phase (Johnson et al., 1993; Shan and Lee, 1994) , and E2F-1 is able to bypass inhibition of cell cycle progression by inhibitors of G1 cyclin/cdk kinase complexes (DeGregori et al., 1995) . Although E2F-1 induces cell proliferation and has oncogenic properties, it also suppresses cell growth and colony formation (Melillo et al., 1994) , and induces cell death by apoptosis in the presence of wild type p53 (Wu and Levine 1994; Qin et al., 1994) .
The transcription factor p53 is also a regulator of the cell cycle and apoptosis, but one that acts in response to DNA damage and cellular stress to maintain genomic integrity and cell cycle checkpoints (for review, see Gottlieb and Oren, 1996; Ko and Prives, 1996) . Like E2F subunits, p53 is also subject to degradation by the ubiquitin-proteasome pathway (Chowdary et al., 1994; Maki et al., 1996) . Here we have studied the expession of E2F, DP and p53 proteins from pCMV expression plasmids in transient transfection assays. We found that expression of E2F-1 and p53 at high levels suppressed expression of proteins from cotransfected genes by squelching mRNA transcription. Although the proteasome inhibitors MG-132 and lactacystin increased the level of expression of E2F-1 and p53, these agents completely abolished squelching by both proteins. Immunofluorescence microscopy and immunoprecipitation experiments indicate that MG-132 and lactacystin alleviate squelching by inhibiting post-translational steps required for proper folding and cellular tracking of p53 and E2F-1.
Results

Suppression of DP-1 expression by cotransfection with E2F-1
Using several human and hamster cell lines, we examined the eect of ectopic expression of E2F and DP proteins on E2F-dependent transcriptional activation of transfected reporter genes. In these experiments, expression of E2F subunits at high levels signi®cantly reduced the expression of DP proteins from cotransfected pCMV expression plasmids. In a typical experiment, cells were transfected with pCMV-E2F-1 or pCMV-DP-1, either alone or together, and the E2F/ DP protein products were detected by Western blotting using monoclonal antibodies that recognize either E2F-1 (KH20) or DP-1 (WTH10). When expressed alone in CHOC 400 cells, both E2F-1 and DP-1 protein appeared within 8 h after the addition of DNA and increased in a time-dependent manner ( Figure 1a and b, lanes 1 ± 6). Cotransfection of pCMV-E2F-1 with pCMV-DP-1 reduced the expression of DP-1 protein nearly 50-fold, while DP-1 reduced the expression of E2F-1 about 3 ± 5-fold ( Figure 1a and b, lanes 7 ± 12).
Suppression of DP-1 expression by E2F-1 was dependent on plasmid DNA concentration ( Figure  2a , lanes 2 ± 5). Like E2F-1, E2F-2 also suppressed expression of DP-1 at low plasmid concentrations ( Figure 2a , lanes 6 ± 9), while E2F-3 and E2F-4 had less of an eect at equivalent plasmid DNA concentrations ( Figure 2a , lanes 10 ± 17). E2Fs 1 ± 4 also suppressed expression of DP-2 protein (Figure 2b ). E2F-4 had little eect on DP-1 expression at concentrations of plasmid DNA up to 8 mg/culture dish, but did suppress the expression of DP-2 in a dose-dependent manner (compare Figure 2a to Figure   2b , lanes 14 ± 17). Western blotting indicated that the levels of expression of E2F proteins varied less than twofold at equivalent plasmid DNA concentrations (data not shown). Suppression of DP-1 protein expression from the pCMV promoter by E2F-1 was also observed in Hela, U2OS and Saos-2 cells (data not shown), as has been reported by others (Hateboer et al., 1996; Hofmann et al., 1996) .
The transactivation domain of E2F-1 is sucient to suppress expression of DP proteins As shown in Figure 3a , E2F-1 has functionally distinct domains that participate in DNA-binding, dimerization with DP-1, transcriptional transactivation, and binding of cyclin A and pRb (Helin et al., 1992; . To determine which domains of E2F-1 were involved in suppression of DP protein expression, altered forms of E2F-1 were coexpressed with DP-1 or DP-2 (Figure 3b and c). Deletion or mutation of the E2F-1 pRb-binding domain (encoded by pCMV-D417-437 and pCMV-Y411C, respectively) did not aect the suppression of DP protein expression (lanes 3 and 6). E2F-1 proteins lacking C-terminal sequences beyond amino acid 374 had no suppressive activity (e.g. pCMV-1 ± 191, pCMV-1 ± 284 and pCMV-1 ± 374), whereas a form of E2F-1 bearing an N-terminal deletion of the domains required for cyclin A binding and DNA-binding (pCMV-223 ± 437) retained the ability to suppress DP-1 and DP-2 expression (lane 5, Figure 3b and c). Thus, only the region between animo acid residues 374 ± 410 that encompasses the transactivation domain of E2F-1 was necessary and sucient for suppressing DP-1 expression.
These results were con®rmed by cotransfection of pCMV-E2F-1 with pCMV plasmids that express truncated forms of hemagglutinin-tagged (HA) DP-1. E2F-1 signi®cantly suppressed expression of all forms of HA-DP-1, including those proteins that bear deletions in DP-1 that are involved in DNA-binding and dimerization with E2F-1 (data not shown). Thus, Suppression of DP-1 expression by E2F-1 and p53 occurs by squelching of mRNA transcription
Since association between E2F-1 and DP-1 was not necessary for the suppressive eect, and only the transactivation domain of E2F-1 appeared to be required to inhibit DP protein expression, we considered it likely that E2F-1 inhibited DP protein expression by squelching, a process in which general transcription factors became sequestered from the transcriptional machinery due to their association with excess transactivation domains (Ptashne 1988) . To determine if the eects of E2F-1 on DP expression occurred at the level of transcription, Northern blotting was used to measure mRNA levels for DP-1, E2F-1, and b-galactosidase (b-gal) in transient transfection experiments. When transfected alone, or with pCMV-b-gal, expression of E2F-1 mRNA from pCMV-E2F-1 increased in time for about 20 h and then decreased thereafter (Figure 4a , lanes 1 ± 5). By 48 h, E2F-1 mRNA was reduced to the level seen 8 ± 10 h after transfection (data not shown). The level of E2F-1 mRNA was only slightly suppressed by cotransfection with pCMV-DP-1 and pCMV-b-gal (Figure 4a , lanes 6 ± 10). In contrast, cotransfection of pCMV-E2F-1 with either pCMV-b-gal (Figure 4b , lanes 6 ± 10) or pCMV-DP-1 (Figure 5c , lanes 6 ± 10) greatly reduced the amount of either b-gal or DP-1 mRNA, respectively.
To con®rm that E2F-1 protein was required for squelching, cells were treated with cycloheximide for 24 h after transfection ( Figure 5 ). Transcription of DP-1 mRNA from pCMV-DP-1 was recovered by the addition of cycloheximide (compare lanes 4 and 8, Figure 5a ), showing that translation of E2F-1 protein was necessary for squelching. The E2F-1 mRNA level was also increased in the presence of cycloheximide (compare lanes 3 ± 4 to lanes 7 ± 8, Figure 5b ), indicating that E2F-1 protein suppressed transcription of pCMV-E2F-1 itself.
To compare the ability of E2F-1 to squelch transcription relative to several other transcription factors, we cotransfected expression vectors for several other transcriptional activators with pCMV-DP-1 and measured DP-1 expression by Western blotting ( Figure  6 ). Expression of c-fos, c-jun, or a combination of both proteins from pRSV expression plasmids had only minimal eect on the expression of DP-1 at any DNA Cotransfection with pUHD-15.1, which encodes a tetracycline receptor-VP16 transactivation domain fusion protein driven by the pCMV promoter (Gossen and Bujard, 1992) , only slightly aected the expression of DP-1 (lane 5). A pUHD control plasmid that expresses luciferase (pUHD-13.1) had no eect (lane 4). In contrast, expression of DP-1 was strongly suppressed by cotransfection with pCMV-p53 (lane 2), but not with pCMV-p53-143 (lane 3), which encodes a tumor-derived form of p53 with a transdominant negative mutation (valine to alanine at amino acid residue 143) that impairs transactivation activity (Kern et al., 1992) .
MG-32 and lactacystin, inhibitors of proteasome protease, prevent transcriptional squelching by E2F-1 and p53
E2F-1 and E2F-4 (Hofmann et al., 1996; Hateboer et al., 1996) and p53 (Chowdary et al., 1994; Maki et al., 1996) are subject to degradation by ubiquitindependent proteolysis. The high molecular weight bands on Western blots for DP-1 suggested that DP-1 also may be covalently modi®ed by polyubiquitination when expressed at high levels (for example, see Figure 6 ). We have shown that DP-1 is an ecient substrate for polyubiquitination in either human or hamster cell lines (J Magae, S Illenye, J Wells, and NH Heintz, manuscript submitted), and that treatment of cell lines with the proteasome inhibitors MG-132 and lactacystin for 24 h increases the level of endogenous E2F-1 and DP-1 approximately 3 ± 5-fold (J Magae and T Tejima, unpublished data). To address the role of ubiquitin-dependent protein degradation in the expression of DP-1, we examined the eect of several protease inhibitors on DP-1 expression levels after transient transfection of pCMV-DP-1 into CHOC 400 cells, with or without cotransfection with pCMV-E2F-1 and pCMV-p53. These experiments revealed that MG-132 and lactacystin alleviate squelching of DP-1 expression by E2F-1 and p53.
The eects of three compounds (ALLN, ALLM, and MG-132) on DP-1 expression were examined ®rst. Cells were transfected and 20 h later the DNA was rinsed from the culture dishes with PBS. MG-132, ALLN, or ALLM then were added with fresh medium for 24 h. Western blotting of cell lysates showed that MG-132 completely prevented squelching of DP-1 expression by E2F-1 (Figure 7a , lane 8) and p53 (lane 12), even though the inhibitor had little eect on DP-1 expression when cells were transfected with pCMV-DP1 alone (lane 4). ALLN and ALLM had little eect on the level of expression of DP-1 from pCMV-DP-1 (lanes 2 and 3), and did not in¯uence squelching by either E2F-2 (lanes 6 ± 7) or p53 (lanes 10 ± 11). Inhibitors of lysosomal acidi®cation, concanamycin B and chloroquine (Woo et al., 1992; Kataoka et al., 1992) , and the protease inhibitors leupeptin and aprotinin also had no eect on squelching of DP-1 expression by E2F-1 and p53 (data not shown).
Remarkably, MG-132 increased the expression of E2F-1 at least 30-fold (Figure 7b , compare lanes 1 ± 4 to lanes 5 ± 8), whether or not DP-1 was expressed. In contrast, p53 protein levels were increased only 3 ± 5-fold by 1.0 mM MG-132 (compare lanes 1 ± 6 to lanes . By 40 h after transfection, MG-132 markedly increased the level of mRNA for E2F-1, either when expressed alone or in combination with DP-1 (data not shown). A second highly speci®c inhibitor of the proteasome, lactacystin (Fenteany et al., 1995) , also increased the expression of E2F-1 ( Figure 8a , lanes 2 ± 4) and prevented squelching of DP-1 expression by E2F-1 (Figure 8b lanes 9 ± 11) or p53 (data not shown). Note that MG-132 and lactacystin prevented squelching by p53 and E2F-1 if added either at the time of DNA (Figure 8 ), or when fresh medium was added after rinsing DNA from the transfected cultures (Figure 7 ).
MG-132 may inhibit folding of wild type p53
While MG-132 and lactacystin induced higher levels of expression of p53 and E2F-1, these compounds prevented squelching by both proteins, suggesting E2F-1 and p53 synthesized in the presence of MG-132 lacked full biological activity. Because mutant forms of p53 were not capable of squelching DP-1 expression at any level of expression ( Figure 6 ; data not shown), we examined the eect of MG-132 on the conformation of wild type p53, using antibodies that preferentially recognize wild type or mutant conformers of the protein (Gannon et al., 1990) . Cells were transfected with pCMV-p53 or pCMVp53-143 and were harvested 24 h after removal of the calcium phosphate-DNA precipitate. 1.0 mM MG-132 was added to replicate plates at the time of addition of DNA, and was maintained in the culture medium throughout the experiment. Cell lysates were prepared and p53 was immunoprecipitated with the monoclonal antibodies Pab240 or Pab1620, which preferentially recognize the mutant and native conformations of p53, respectively (Gannon et al. 1990 ). The p53-antibody complexes were captured with anti-mouse IgG agarose, resolved by polyacrylamide gel electrophoresis, and p53 levels were detected by Western blotting with horse radish peroxidase (HRP)-conjugated p53 antibody DO-1.
As shown in Figure 9a , monoclonal antibody Pab1620 preferentially recognized wild type p53 (lane 2), while monoclonal antibody Pab240 preferentially 8) . Western blotting of the lysates indicated that the level of expression of wild type p53 and p53-V143A was similar with or without MG-132 (lanes 9 ± 12). These data suggested MG-132 may in¯uence the conformation of newly synthesized p53.
To assess this possibility further, we examined the eect of MG-132 on the association of endogenous p53 with the molecular chaperone hsp70. U2OS cells were treated with actinomycin D and/or MG-132, and the association of hsp70 with wild type p53 in cell extracts was determined by co-immunoprecipitation experiments. Upon treatment with 2 ng/ml actinomycin D, p53 levels in U2OS cells increased signi®cantly by 24 h (Figure 9b, compare lanes 1 and 2) . MG-132 also induced the accumulation of endogenous p53 in U2OS cells, but to a lesser extent than actinomycin D (compare lanes 2 and 3). MG-132 inhibited the accumulation of p53 by actinomycin D (compare lanes 2 and 4), suggesting MG-132 abrogates the response to actinomycin D even though it increases p53 levels. When p53 was immunoprecipitated from U2OS cell extract, the amount of hsp70 that coprecipitated with p53 was markedly increased by MG-132, but not by actinomycin D (Figure 9b, compare lanes 2 and 3) .
MG-132 inhibits the nuclear accumulation of E2F-1 and p53
While immunoprecipitation experiments indicated that MG-132 alters the conformation of wild type p53, the lack of immune reagents speci®c for dierent conformers prevented a similar examination of the efect MG-132 on E2F-1. To determine if MG-132 also alters E2F-1, indirect immuno¯uorescence microscopy was used to examine the eects of MG-132 on cellular tracking of E2F-1. We also examined the eect of MG-132 on nuclear accumulation of p53 and the pocket protein p107.
E2F-1 normally is found in the cell nucleus after ectopic expression from pCMV-E2F-1 (Magae et al., 1996, and Figure 10 ). In the presence of 1.0 mM MG-132, E2F-1 was found distributed throughout both the cell cytoplasm and the nucleus (Figure 10 ). Similarly, wild type p53, which is normally nuclear in location, also was found to be distributed throughout both the cytoplasm and nucleus in the presence of MG-132 (Figure 10 ). MG-132 does not universally inhibit the accumulation of proteins in the nucleus, for it had little efect on nuclear localization of the pRb-related protein p107 (Figure 10 ). In E1-12 cells, a stablytransfected CHO cell strain that expresses E2F-1 from a tetracycline-responsive promoter (J Magae, S Illenye, J Wells and NH Heintz, manuscript submitted), MG-132 also markedly inhibited nuclear accumulation of E2F-1 without altering E2F-1 mRNA levels (data not shown). Lactacystin also inhibited cytoplasmic clearing of E2F-1 in E1-12 cells, and E2F-1 and p53 in transient transfection experiments in both human and hamster cells (data not shown).
Discussion
We have examined ectopic expression of E2F and DP proteins in an eort to understand the eects of dierent levels of these factors on transcription, cell cycle progression, and apoptosis. In CHOC 400, as well as Saos-2, U2OS, and C33A cells, expression of E2F-1 at high levels suppressed transcription from cotransfected pCMV expression vectors. The suppressive eect of E2F-1 on transcription has been noted by others (Hateboer et al., 1996; Hofmann et al., 1996) . Like E2F-1, p53 also suppressed the transcription of mRNA from cotransfected plasmids. Although transcriptional activators stimulate the assembly and function of preinitiation complexes composed of RNA polymerase II and general transcription factors (reviewed by Zawel and Reinberg, 1993) , overexpression of transactivators can inhibit transcription through a process called squelching. When expressed at high levels, activation domains may sequester general transcription factors from the transcription initiation complex, and thereby reduce transcription in a promoter-independent fashion (Ptashne, 1988) . Since domain mapping experiments show that only sequences that encompass the transcriptional activation domain of E2F-1 are required for suppression of transcription from the pCMV promoter, and a transcriptionally inactive form of p53 was ineective in suppressing mRNA expression, the phenomenon we report here represents a classic example of transcriptional squelching. The target of squelching by E2F-1 and p53 may be TFIID, a general transcription factor required for the nucleation of new transcription complexes on pol II promoters. Since E2F directly binds to TATA-binding protein (TBP) through its transactivation domain (Hagemeier et al., 1993; Emili and Ingles, 1995) , it is reasonable to assume that overexpression of E2F-1 titrates TFIID through interactions with TBP. Wild type p53 also has been shown to inhibit transcription by interactions with TBP in vivo (Seto et al., 1992; Mack et al., 1993; Liu et al., 1993; Martin et al., 1993; Truant et al., 1993) . In vitro, addition of excess TFIID and TFIIB reverse squelching by p53 (Liu and Berk, 1995) . Thus, TFIID may represent the common target for squelching by E2F-1 and p53. However, coexpression of TBP with E2F-1 or p53 did not alleviate squelching (data not shown).
While each E2F subunit inhibited DP protein expression, the suppressive activity was most potent 
+MG132
Figure 10 MG-132 inhibits cytoplasmic clearing of E2F-1 and p53. Cells were transfected with pCMV-E2F-1, pCMV-p53, or pCMV-p107. Twenty hours after addition of DNA, cells were washed with PBS and incubated in culture medium alone or culture medium containing 1.0 mM MG-132. After 40 h, the cultures were processed for indirect immuno¯uorescence microscopy to determine the intracellular distribution of E2F-1, p53, and p107. FITC indicates the green signal from the secondary FITCconjugated rabbit anti-mouse antibody, the red propidium iodide (PI) signal reveals the location of the cell nucleus, and FITC/PI shows the distribution of both signals. The primary antibodes were KH20 for E2F-1, Pab421 for p53, and a mixture of SD2, SD4, SD9, and SD15 for p107
for E2F-1 and E2F-2. Only E2F-4 suppressed expression of DP-2 greater than DP-1 (Figure 2) . Immunolocalization of E2F subunits showed E2F-4 is mainly localized in cytoplasm when expressed ectopically, while E2F-1, -2 and -3 readily accumulate in the nucleus (Magae et al., 1996) . Co-expression of DP-2 promotes higher levels of nuclear E2F-4 protein than does DP-1 (Magae et al., 1996) , suggesting DP-2 may promote entry of E2F-4 into the nucleus and thereby potentiate its ability to squelch transcription.
MG-132 and lactacystin in¯uence the conformation of p53
MG-132 and lactacystin are both highly speci®c inhibitors of proteasome protease (Palombella et al., 1994; Fenteany et al., 1995) . Treatment of several cell types for 24 h with these drugs increases the level of many proteins, including p53, p21, mdm2, bax and E2F-1, by 3 ± 10-fold ( Figure 9b ; Magae et al., manuscript in preparation). Since these endogenous proteins are targeted for degradation by the ubiquitinproteasome pathway, these increases are likely due to inhibition of protein degradation. In contrast, in transient transfection experiments similar concentrations of MG-132 and lactacystin increase the level of expression of p53 and E2F-1, with E2F-1 expression increasing up to 50-fold in some experiments. Examination of mRNA levels showed the large increases in expression induced by MG-132 and lactacystin were due to alleviation of squelching, leading to increased levels of transcription from cotransfected pCMV expression plasmids. The observation that MG-132 and lactacystin increased E2F-1 and p53 protein levels but coincidentally alleviated squelching suggested the inhibitors not only inhibit the degradation of these transcription factors, but also in¯uence their biological function. Because MG-132 and lactacystin were added at the time of DNA in transfection experiments, and full length proteins were synthesized, the cellular processes that are disrupted by MG-132 and lactacystin must occur after translation and prior to association of E2F-1 and p53 with general transcription factors in the nucleus. They are unlikely to be related to the functions of p53 and E2F-1 in regulating transcription during cell growth, for p53 impedes cell proliferation and E2F-1 accelerates it. After translation, nascent polypeptides associate with a series of protein factors, including heat shock proteins, that mediate protein folding (reviewed by Hendrick and Hartl, 1993) . In immunoprecipitation experiments, MG-132 consistently increased the fraction of wild type p53 that was recognized by monoclonal antibody Pab240 (Figure 9a ), which preferentially detects conformations speci®c for mutant forms of p53 (Gannon et al., 1990) . MG-132 markedly increased the fraction of wild type p53 associated with hsp70 (Figure 9b) , a molecular chaperone which associates only with mutant forms of p53 (Sturzbecher et al., 1988; Finlay et al., 1988) . In vitro, hsp70 associates with mutant, but not wild type, p53 immediately after translation (Hainaut and Milner, 1992) . Together these results indicate that MG-132 (and lactacystin) interfere with one or more steps in the processing of nascent p53 polypeptide, leading to the accumulation of a cytoplasmic conformer of p53 that is preferentially bound by hsp70.
Because immune reagents speci®c for various conformers of E2F-1 are not available, we were unable to test if MG-132 also aects the conformation of the E2F-1 polypeptide in a similar manner. However, immunolocalization studies in both human and hamster cells shows that MG-132 inhibits nuclear accumulation of E2F-1. This eect is not a result of general inhibition of nuclear transport, for the compound had no eect on the nuclear localization of p107 (Figure 10 ), nor did preincubation of BHK cells with 1.0 mM MG-132 for 20 h in¯uence the entry of a GFP-glucacorticoid receptor fusion protein into the nucleus (K Carey, NH Heintz and I Macara, unpublished data). Therefore, as for p53, the inhibitory eect of MG-132 on accumulation of E2F-1 in the nucleus appears to result from an indirect eect on protein conformation.
There are several possibilities for these results. First, MG-132 and lactacystin could inhibit the turnover of a cytoplasmic factor that negatively regulates nuclear entry of E2F-1 and p53. Cytoplasmic retention of a temperature-sensitive mutant of p53 at the nonpermissive temperature has been attributed to a short-lived protein (Gannon and Lane, 1991) . Although the identity of this factor is unknown, it may act in common on misfolded forms of wild type p53 and E2F-1. Second, MG-132 and lactacystin could have cellular targets in addition to the proteasome that in¯uence post-translational steps involved in folding and tracking of E2F-1 and p53. Third, like the p105 precursor protein of the p50 subunit of NF-kB (Palombella et al., 1994) , it is possible nascent E2F-1 and p53 polypeptides must be processed by the proteasome in order to acquire full biological activity. Although the apparent molecular weights of E2F-1 and p53 generated during transient transfection experiments correlate well with their predicted sizes and comigrate on SDS gels with their endogenous counterparts, our data does not exclude this possibility. Finally, the proteasome may play a role in monitoring p53 and E2F-1 protein folding.
MG-132 is known to inhibit the ATP-dependent conversion of precursor protein into mature cystic ®brosis transporter (CFTR) in the endoplasmic reticulum (Jensen et al., 1995) . Unlike MG-132, however, lactacystin did not inhibit the conversion of the immature form of CFTR to the mature form, but did slow the bulk degradation of mature (CFTR (Jensen et al., 1995) . Along with CFTR, studies on other secreted proteins suggest the proteasome plays a quality control role in the metabolism of misfolded proteins that trac through the endoplasmic reticulum (reviewed by Kopito 1997). In some instances, ubiquitination of such misfolded proteins is not readily detectable.
If the proteasome plays a similar role in monitoring protein folding in the cytoplasm, accumulation of misfolded p53 and E2F-1 in the presence of MG-132 may re¯ect a high rate of unsuccessful folding of these factors. A number of other transcription factors, including NFkB, c-fos, c-jun and p53 are stabilized by MG-132 and lactacystin, but stabilization is not always accompanied by a corresponding accumulation of polyubiquitinated forms of the protein (Palombella et al., 1994; Treier et al., 1994; Ciechanover et al., 1991; Schener et al., 1994; Maki et al., 1996) . Misfolding of transcription factors could occur at high rate naturally, perhaps due to the¯exible structure of transactivation domains, or MG-132 and lactacystin could directly or indirectly induce misfolding. Here we also failed to observe large increases in the accumulation of polyubiquitinated forms of p53 and E2F-by either MG-132 or lactacystin (Figures 7  and 8 ), suggesting that either polyubiquitination is not always required to deliver misfolded proteins to the proteasome, or that the inhibitors have other cellular targets. At present we are attempting to determine if p53 synthesized in the presence of MG-132 is in a conformation that can be activated for DNA binding.
Finally, our observations raise the possibility that the cytoxic eects of E2F-1 and p53 may result in part from transcriptional squelching. The adenovirus oncoprotein E1A induces apoptosis by a mechanism that depends on wild type p53, and apoptosis is inhibited by oncoproteins 19 kD E1B and Bcl-2 (Rao et al., 1992; Debbas and White, 1993) . Since E1A binds to pRb and releases the active form of E2F-1 (Whyte et al., 1988; Bagchi et al., 1991; Bandara and La Thangue, 1991; Chellapan et al., 1991; Weintraub et al., 1992) , E1A-mediated apoptosis may be related to inappropriate activation of E2F-1. Similarly, ectopic expression of E2F-1 induces apoptosis in p53-dependent manner (Wu et al., 1994; Qin et al., 1994) . Although the requirement for p53 in apoptosis is not entirely clear, there is evidence that transcriptional repression by p53 plays a role in p53-mediated apoptosis. For example, Bcl-2 and E1B 19 kD oncoproteins abrogate p53-mediated repression of transcription from promoters that lack p53 binding sites (Shen and Shenk, 1994; Sabbatini et al., 1995) .
Materials and methods
Plasmids
Expression vectors for c-jun and c-fos were provided by A Berk and p53 and p53V143P from D Haber. All other plasmids were constructed as described previously (Helin et al., 1992 Wu et al., 1995) . Plasmids were puri®ed by banding on CsCl density gradients twice and were used for transfection as previously described .
Antibodies
Monoclonal antibodies used for Western blotting and immunofluorescence were KH20 for E2F-1 , WTH10 for DP-1 (Wu et al. 1995) , BC2 for DP-2, Pab412, Pab1620 and DO-1 for p53 (Santa Cruz), SD2, SD4, SD9, and SD15 for p107 (from N Dyson), and 12CA5 for hemagglutinin-tagged DP-1. Immunohistochemical visualization of the intracellular localization of E2F-1 and p53 was performed as described previously (Magae et al., 1996) . FITC-conjugated rabbit anti-mouse immunoglobulin for immuno¯uorescence and horse radish peroxidase-conjugated anti-mouse immunoglobulin for Western blotting were purchased from Amersham (Arlington Height, IL).
Chemicals
MG-132 was kindly donated by Proscript
and ALLM (N-acetyl-L-leucinyl-L-leucinyl-L-methonal) were purchased from Sigma. Lactacystin was purified as previously described (Ō mura et al., 1991) .
Cell culture and transfection
CHOC 400 cells, a methotrexate-resistant CHO cell line which bears amplified dehydroforate reductase genes (Milbrandt et al., 1981) , was cultured in 5% CO 2 atmosphere at 378C using D-MEM supplemented with 5% fetal bovine serum and 0.05 mg/ml kanamycin (GIBCO-BRL). CHOC 400 cells were plated at 1610 6 cells/100 mmdiameter culture dish in 10 ml medium. After incubation overnight, fresh medium was added for 6 h prior to addition of calcium phosphate/DNA precipitates (expression vectors plus salmon sperm carrier DNA equaled 24 mg DNA/dish). The cultures were incubated an additional 18 ± 20 h, washed with phosphate-buered saline (PBS, pH 7.5, 0.8% NaCl) three times and incubated in fresh culture medium with or without inhibitors until processed for RNA or protein extracts. CHOC 400 cell strain E1-12 was cultured in 5% CO 2 atmosphere at 378C using D-MEM supplemented with 5% fetal bovine serum and 1.0 mg ml tetracycline. To induce E2F-1 expression in E1-12 cells, cells were washed three times and incubated in fresh medium lacking tetracycline.
Western blotting
Cells were scraped from culture dish, suspended in SDS sample buffer (2% SDS, 0.1 M dithiothreitol, 0.01% bromophenol blue, 20% glycerol, 120 mM Tris/HCl, pH 6.8) by sonicating for 5 s and heated at 958C for 10 min. Equal amounts of protein extract were resolved by 8% SDS ± PAGE and transferred to membrane (Immobilon-P, Milipore). The membrane was soaked in blocking buer (5% non-fat dry milk, 0.1% Tween 20, 0.8% NaCl, 20 mM Tris/HCl, pH 7.5) for 1 h, incubated with primary antibody diluted 1 : 5 with blocking buer for 1 h, washed 36 in blocking buer, and incubated with horse radish peroxidase (HRP)-conjugated secondary antibody (either anti-mouse or anti-rabbit immunoglobulin) diluted 1 : 1000 with blocking buer for 1 h. The blot was then washed 56 in blocking buer, and speci®c signals were detected by enhanced chemiluminescence (ECL, Amersham).
Northern blotting
RNA was prepared and analysed by Northern blotting as described previously (Shull et al., 1991) . Probes were labeled with 32 P-dCTP using the Gibco-BRL random primer kit. Blots were exposed to X-Omat ®lm (Kodak) for 1 ± 3 days with intensifying screens.
Immunoprecipitation of p53
From CHOC 400 cell extracts: CHOC 400 cells were plated at a density of 1610 6 /100 mm culture dish, incubated overnight, and transfected with pCMV-p53 or pCMV-p53 V143A . After 16 h, the cells were washed 36 with PBS, and incubated for an additional 24 h in fresh medium. MG-132 (1.0 mM) was added at the time of the addition of DNA and maintained in the medium throughout the experiment. For each sample, cells from three dishes were pooled and suspended in 300 ml of cell lysis buer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 1 mM PMSF, 5 mM EDTA) (Gannon et al., 1990) . After 60 min on ice, the lysate was cleared by centrifugation, and 100 ml of the supernatant was diluted 1 : 5 with PBS and incubated with 2 mg of either Pab240 or Pab1620 (Santa Cruz) for 60 min on ice on a rocking platform. Anti-mouse IgG agarose (20 ml wet volume, Sigma) was added and the samples were incubated on ice with mixing for an additional 60 min. The agarose beads were then washed with TBS containing 0.1% Tween 20 (TBS-T) 6X, suspended in 100 ml of 26 sample buer, heated at 958C for 5 min, and centrifuged in a microfuge for 3 min. For measuring protein levels in cell lysates, 25 ml of cleared lysate was diluted in an equal volume of 26SDS sample buer. Ten ml of samples from the lysates and immunoprecipitations were resolved on an 8% polyacrylamide SDS gel, and transferred to membrane as above. After blocking, the membrane was incubated with horse radish peroxidase (HRP)-conjugated anti-p53 antibody DO-1 (Santa Cruz), washed 46 with blocking buer (TBS with 5% skim milk, 0.1% Tween 20), and p53 was visualized with ECL reagents (Amersham) and XOmat X-ray ®lm (Kodak).
From U2OS cell extracts: 2610 6 cells were suspended in 100 ml of cell lysis buer, incubated on ice for 1 h, and then centrifuged for 10 min at 14K r.p.m. in a microfuge at 48C. The supernatant was diluted 1 : 3 with PBS, and 1 mg each of monoclonal antibodies Pab1620 and Pab240 was added. After rocking for 1 h at 48C, anti-mouse IgG agarose was added, and the sample was incubated with rocking for an additional 1 h at 48C. The beads were then washed 66 with ice cold TBS-T and resuspended in SDS sample buer. After heating, the samples were resolved by 8% SDS ± PAGE. The signals for HSP70 and p53 were detected by ECL using anti-HSP72/73 monoclonal antibody (Santa Cruz) and HRP-conjugated anti-p53 monoclonal antibody DO-1, respectively.
